SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : sciclone pharmaceuticals
SCLN 11.150.0%Oct 20 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Skywatcher who wrote ()2/4/2000 11:32:00 AM
From: 5handicap  Read Replies (1) of 1137
 
I've been looking at yesterday's numbers, and would like to point out a few things. Did anyone notice the "cost of product" as a percentage of the "product revenues"? 28.6% in 1998, while in 1999 it has dropped to 19.4%. Economy of scale is kicking in already, it's getting cheaper to make every vial of zadaxin.
The contract revenue decreased to zero as the company focused on selling a product. While R&D expenses were halved in 1999 compare to 1998, Marketing expenses increased less than 10%, and administrative expenses decreased 25%. Looks like excellent management to me.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News